Trial Profile
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Milatuzumab-doxorubicin conjugate (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Immunomedics
- 02 Mar 2020 Status changed from completed to discontinued.
- 22 Jan 2014 Status changed from suspended to completed according to ClinicalTrials.gov record .
- 18 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.